| P/E (FY) | — | Sales (TTM) | $89.4M |
| Earnings (TTM) | -$221.3M | ROE | −16.23% |
| Net Margin | −30.77% | ROIC | −24.84% |
| Debt / Equity | 0.00 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 25.96% |
Arvinas, Inc. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of therapies that degrade disease-causing proteins. It develops proteolysis targeting chimeras (PROTAC) targeted protein degraders designed to harness the body's natural protein disposal system. Its programs include ARV-102 for neurodegenerative diseases, ARV-806 for cancers with the G12D mutation, ARV-393 for non-Hodgkin lymphoma, and ARV-027.
| Market Cap | $529.1M | Trading Days | 1964 |
| 52W High | 14.51 |
| 52W Low | 6.06 |
| % Off High | −43.49% |
| YTD | −30.86% | 1Y | 7.75% |
| 3Y | −63.43% | 5Y | −92.10% |
| Since incept. (ann.) | −8.22% |
Reportable 100%
| Ann. Volatility (1Y) | 55.45% | Ann. Volatility (3Y) | 70.45% |
| Sharpe (1Y) | 0.41 | Sharpe (3Y) | −0.08 |
| Max Drawdown (1Y) | −48.73% | Max Drawdown (3Y) | −88.40% |
| Beta (3Y, vs SPY) | 2.52 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | $525.7M | — |
| NGNE | Neurogene Inc. | $524.9M | — |
| STTK | Shattuck Labs, Inc. | $523.0M | — |
| MPLT | MapLight Therapeutics, Inc. | $522.4M | — |
| VSTM | Verastem, Inc. | $547.5M | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $548.6M | — |
| SPRY | ARS Pharmaceuticals, Inc. | $563.0M | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $575.2M | 7.2 |
| CRMD | CorMedix Inc. | $576.6M | 3.6 |
| GYRE | GYRE THERAPEUTICS, INC. | $581.2M | 58.8 |
| ALT | Altimmune, Inc. | $581.5M | — |
| Rezolute, Inc. |
| $473.8M |
| — |
